The Q4 FY26 results paint a grim picture of a company struggling with operational viability. Net sales collapsed to zero in the March 2026 quarter, down from ₹1.21 crores in Q3 FY26 and ₹0.71 crores in the year-ago quarter. This complete absence of revenue generation underscores the company's inability to conduct meaningful business activities, a pattern that has persisted across recent quarters with only sporadic income recognition.
The net loss of ₹0.16 crores in Q4 FY26 represents a sharp deterioration from the ₹0.04 crores loss in Q3 FY26, driven primarily by an unusual tax charge of ₹0.11 crores despite the company operating at a loss. This anomalous tax situation, reflected in a negative tax rate of -220.00%, further compounds the financial distress and raises questions about legacy tax liabilities or adjustments.
Financial Performance: A Company Without Revenue
The quarterly trend reveals a company that has essentially ceased operations as a functional NBFC. Across the past seven quarters, Roselabs Finance has generated revenue in only two quarters—₹0.71 crores in Q4 FY25 and ₹1.21 crores in Q3 FY26—whilst recording zero sales in all other periods. This erratic pattern suggests the company is no longer actively engaged in lending or financial services, the core activities that define an NBFC.
| Quarter | Net Sales (₹ Cr) | Net Profit (₹ Cr) | QoQ Change | YoY Change |
|---|---|---|---|---|
| Mar'26 | 0.00 | -0.16 | -300.00% | -220.00% |
| Dec'25 | 1.21 | -0.04 | -33.33% | -63.64% |
| Sep'25 | 0.00 | -0.06 | +20.00% | -33.33% |
| Jun'25 | 0.00 | -0.05 | 0.00% | N/A |
| Mar'25 | 0.71 | -0.05 | +54.55% | N/A |
| Dec'24 | 0.00 | -0.11 | 0.00% | N/A |
| Sep'24 | 0.00 | -0.09 | N/A | N/A |
Operating losses before interest, depreciation, and tax (PBDIT) stood at ₹-0.05 crores in Q4 FY26, marginally worse than the ₹-0.03 crores loss in the previous quarter. With negligible employee costs of just ₹0.01 crores and no significant operational expenses, the company appears to be in a minimal maintenance mode, incurring basic corporate overheads without generating any corresponding income.
The absence of interest expenses across all recent quarters indicates the company has no active borrowing-based lending operations, which is unusual for an NBFC and further confirms the cessation of core business activities. Similarly, depreciation remains at zero, suggesting no fixed asset base or capital investments.
Critical Financial Red Flags
Negative Book Value: At ₹-4.73 per share, shareholder equity has been completely eroded, with reserves and surplus at ₹-14.73 crores against share capital of ₹10.00 crores. This represents a fundamental impairment of the balance sheet.
No Revenue Generation: The company has failed to generate consistent revenue across the past seven quarters, with only sporadic income recognition that does not reflect sustainable business operations.
Persistent Losses: Continuous quarterly losses ranging from ₹0.04 crores to ₹0.16 crores demonstrate an inability to achieve even operational break-even despite minimal expenses.
Balance Sheet Deterioration: Negative Equity and Rising Debt
The balance sheet as of March 2025 (latest available annual data) reveals the extent of financial distress. Shareholder funds stand at ₹-4.73 crores, comprising share capital of ₹10.00 crores offset by accumulated losses of ₹-14.73 crores in reserves and surplus. This negative net worth means the company's liabilities exceed its assets, a situation that typically triggers insolvency concerns.
Long-term debt has increased to ₹4.93 crores in FY25 from ₹4.57 crores in FY24, indicating the company continues to carry debt obligations despite generating no meaningful revenue. The debt-to-equity ratio stands at -1.02, though this metric is distorted by the negative equity base. In practical terms, the company has debt but no equity cushion to absorb losses.
Current assets of just ₹0.12 crores as of March 2025 are dwarfed by current liabilities, and the company holds no investments or fixed assets of note. This asset-light structure, combined with negative working capital, leaves Roselabs Finance with virtually no resources to revive operations or service existing obligations.
Return on Equity: A Meaningless Metric for Negative Book Value
Traditional profitability metrics become largely irrelevant when a company operates with negative shareholder equity. The reported return on equity (ROE) of 0.0% understates the severity of the situation—with negative book value, the company is destroying rather than creating shareholder value with each passing quarter of losses.
Return on capital employed (ROCE) of -31.00% further illustrates the company's inability to generate positive returns from the capital at its disposal. This negative ROCE, combined with the absence of revenue, signals that the company is consuming capital rather than deploying it productively—a fundamentally unsustainable position for any financial services entity.
The Lodha Group Connection: Limited Comfort
Roselabs Finance became a subsidiary of Arihant Premises Private Limited, itself a step-down subsidiary of Lodha Developers Private Limited, in June 2013. Whilst the association with the prominent Lodha Group might suggest potential support, the continued deterioration of Roselabs Finance's financials over multiple years indicates limited appetite or strategic interest from the parent in reviving this entity. The 74.25% promoter holding has remained unchanged across recent quarters, showing neither increased commitment nor divestment.
Peer Comparison: The Weakest Link in a Struggling Segment
Comparing Roselabs Finance to other micro-cap NBFCs reveals just how distressed the company's position has become. Whilst several peers also face challenges, none exhibit the combination of negative book value, zero revenue generation, and persistent losses that characterise Roselabs Finance.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity |
|---|---|---|---|---|
| Roselabs Finance | NA (Loss Making) | -4.87 | 0.0 | -1.02 |
| Vertex Securities | NA (Loss Making) | 2.90 | 3.39 | 0.87 |
| Morarka Finance | 13.09 | 0.23 | 2.01 | 0.00 |
| Swarna Securities | 30.38 | 3.43 | 0.0 | 0.00 |
| Darjeeling Industries | 11.62 | 5.09 | 0.0 | 0.26 |
| Visagar Financial | NA (Loss Making) | 0.38 | 2.51 | 0.65 |
Roselabs Finance stands out unfavourably across all metrics. Its negative price-to-book value of -4.87x reflects the market's recognition that the company trades purely on speculative grounds, with no fundamental value support. Peers like Morarka Finance and Swarna Securities, whilst small, at least maintain positive book values and some level of profitability or operational activity.
The company's ROE of 0.0% trails peers such as Vertex Securities (3.39%) and Visagar Financial (2.51%), though this comparison is somewhat academic given Roselabs' negative equity base. More concerning is the complete absence of revenue generation, which distinguishes Roselabs Finance from even the weakest performers in its peer group.
Valuation Analysis: Risky and Uninvestable
The current valuation assessment of "RISKY" understates the gravity of the investment proposition. With a negative book value and no earnings, traditional valuation metrics such as P/E ratio and P/BV become meaningless or deeply negative. The stock trades at ₹24.00 against a book value of ₹-4.73, implying investors are paying for a company whose liabilities exceed its assets.
The enterprise value-to-sales ratio of 28.44x appears extremely elevated, though this metric is distorted by the sporadic and minimal revenue recognition. More telling is the negative EV/EBITDA of -28.44x, reflecting the company's inability to generate positive operating cash flows.
The stock's 52-week range of ₹19.57 to ₹35.67 shows significant volatility, typical of distressed micro-caps where price movements reflect speculation rather than fundamental developments. Currently trading 32.72% below its 52-week high, the stock has given back most of its earlier gains, though it remains 22.64% above its 52-week low.
Shareholding Pattern: Promoter Lock-in with Zero Institutional Interest
The shareholding pattern reveals a company that has completely failed to attract institutional interest, with foreign institutional investors (FIIs), mutual funds, and insurance companies maintaining zero exposure across all recent quarters. This absence of institutional participation speaks volumes about the company's perceived viability and investment merit.
| Category | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 74.25% | 74.25% | 74.25% | 0.00% |
| FII | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual Funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-Institutional | 25.75% | 25.75% | 25.75% | 0.00% |
Promoter holding has remained static at 74.25% across recent quarters, controlled entirely by Lodha Developers Limited through its subsidiary structure. The lack of any promoter buying despite the stock's distressed valuation suggests limited confidence in near-term recovery prospects. Conversely, the absence of selling may simply reflect the illiquid nature of the stock and the challenges of finding buyers for such a fundamentally impaired entity.
The 25.75% non-institutional holding represents retail investors and speculators, likely attracted by the low absolute price and occasional volatility spikes. The complete absence of any domestic institutional investor (DII) participation—with no mutual funds, insurance companies, or other institutions holding even a single share—underscores the company's status as uninvestable from a professional fund management perspective.
Stock Performance: Short-Term Gains Mask Long-Term Destruction
The stock's recent price performance presents a misleading picture when viewed in isolation. Whilst Roselabs Finance has gained 2.13% in the past day and 16.56% year-to-date (YTD) in 2026, these short-term movements reflect speculative trading rather than fundamental improvement. The YTD gain significantly outpaces the Sensex's -8.24% decline, generating positive alpha of 24.80%, though this comparison is meaningless given the vastly different risk profiles.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | 1.14% | 0.84% | +0.30% |
| 1 Month | 3.23% | 2.80% | +0.43% |
| 3 Months | -6.61% | -6.42% | -0.19% |
| 6 Months | -25.00% | -6.85% | -18.15% |
| 1 Year | -25.00% | -0.45% | -24.55% |
| 3 Years | 52.77% | 30.53% | +22.24% |
| 5 Years | -24.88% | 60.14% | -85.02% |
| 10 Years | -43.53% | 205.16% | -248.69% |
The longer-term picture reveals catastrophic value destruction. Over one year, the stock has declined 25.00%, underperforming the Sensex by 24.55 percentage points. The five-year return of -24.88% compares dismally to the Sensex's 60.14% gain, representing an alpha of -85.02%. Most damning is the 10-year performance: whilst the Sensex has surged 205.16%, Roselabs Finance has lost 43.53% of its value, an alpha of -248.69 percentage points.
The stock's high volatility of 56.86% over the past year, compared to the Sensex's 13.47%, reflects its speculative nature and thin trading volumes. With a beta of 1.50, the stock exhibits 50% more volatility than the broader market, though this elevated risk has not been compensated with returns—the risk-adjusted return of -0.44 confirms a "high risk, low return" profile.
The NBFC sector has delivered 12.83% returns over the past year, meaning Roselabs Finance has underperformed its own sector by a massive 37.83 percentage points. This underperformance reflects the market's recognition that Roselabs Finance bears little resemblance to a functioning NBFC and should not be evaluated alongside operational financial services companies.
Technical Analysis: Mildly Bearish Trend with Limited Support
From a technical perspective, the stock remains in a "mildly bearish" trend since March 30, 2026, having previously been in a full bearish trend since late October 2025. The current price of ₹24.00 sits below key moving averages, including the 5-day MA (₹24.24), 20-day MA (₹23.02), 50-day MA (₹22.87), and 100-day MA (₹24.42), though the proximity to these levels suggests the stock is range-bound rather than trending strongly in either direction.
Technical indicators present mixed signals. The MACD shows "mildly bullish" on a weekly basis but remains "bearish" on a monthly timeframe, whilst the RSI provides no clear directional signal. Bollinger Bands indicate "mildly bullish" weekly but "mildly bearish" monthly, reflecting the stock's choppy, directionless price action characteristic of illiquid, fundamentally challenged securities.
Support appears at the 52-week low of ₹19.57, whilst resistance emerges at the 20-day MA area around ₹23.02, the 100-day MA at ₹24.42, and ultimately the 52-week high of ₹35.67. Given the fundamental deterioration, technical levels offer limited predictive value—price movements likely reflect sporadic speculative interest rather than sustainable trends.
Investment Thesis: No Credible Path to Recovery
The proprietary Mojo Score of 17 out of 100 and "STRONG SELL" rating accurately capture the investment case—or rather, the lack thereof. This score places Roselabs Finance firmly in the lowest category, reflecting multiple structural problems that show no signs of resolution.
The Mojo 4 Dots Analysis reveals uniformly negative signals: valuation is "RISKY" (reflecting negative book value and lack of earnings), quality is "BELOW AVERAGE" (generous given the operational cessation), financial trend is "FLAT" (understating the deterioration), and technicals are "MILDLY BEARISH" (the only metric showing any ambiguity).
Limited Positives
- Lodha Group association provides theoretical backstop, though no evidence of support
- Minimal debt servicing costs due to low interest burden
- Low absolute share price may attract speculative interest
- Stable promoter holding indicates no forced selling pressure
- Extremely low trading volumes limit downside liquidity risk for small positions
Critical Risk Factors
- Negative book value of ₹-4.73 per share indicates complete equity erosion
- Zero revenue generation in most quarters signals operational cessation
- Persistent quarterly losses with no path to profitability
- Negative ROCE of -31.00% reflects capital destruction
- Complete absence of institutional investor interest
- High volatility (56.86%) without compensating returns
- Massive long-term underperformance vs. market and sector
- No visible business plan or strategic direction
- Rising debt despite no revenue-generating operations
- Illiquid stock with minimal trading volumes
Outlook: What to Watch (Though Recovery Appears Unlikely)
Potential Positive Catalysts
- Capital infusion from Lodha Group to restore positive net worth
- Strategic restructuring or business model pivot
- Asset monetisation to reduce debt burden
- Merger or acquisition by stronger NBFC entity
Red Flags to Monitor
- Further deterioration in book value below current ₹-4.73
- Continued absence of revenue generation in upcoming quarters
- Any increase in debt levels without corresponding asset growth
- Regulatory action due to negative net worth (RBI norms for NBFCs)
- Promoter stake dilution or pledging
The Verdict: Uninvestable on All Metrics
Score: 17/100
For Fresh Investors: Avoid entirely. The combination of negative book value, zero revenue generation, persistent losses, and complete absence of institutional interest makes this an uninvestable proposition. The low absolute price is a value trap, not a value opportunity.
For Existing Holders: Exit at the earliest opportunity, even at current depressed levels. The company shows no credible path to operational recovery, and continued holding exposes investors to further capital erosion and potential delisting risk. Any short-term price spikes should be used as exit opportunities rather than reasons for optimism.
Fair Value Estimate: Not applicable (negative book value renders traditional valuation meaningless; intrinsic value likely zero or negative)
Roselabs Finance exemplifies a distressed micro-cap NBFC that has ceased meaningful operations whilst continuing to incur losses and accumulate debt. With negative shareholder equity, no revenue generation, and zero institutional support, the company faces potential insolvency or regulatory intervention. The "STRONG SELL" rating reflects not just poor fundamentals but the absence of any viable investment thesis or recovery scenario.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. The analysis presented herein is based on publicly available information and historical data, which may not reflect current or future performance. Past performance is not indicative of future results. Investments in micro-cap stocks, particularly those with negative book value and operational challenges, carry substantial risk of capital loss.
